Anti-vaccine antibodies against measles, rubella, parotitis and hepatitis B in children with inflammatory bowel disease and healthy controls

Table 1 Demographic characteristics of patients with inflammatory bowel diseases, included in the study, n (%)/median (25^th-75^th percentiles)

Parameter	n = 98
Sex, females	46 (47.2)
Age of the inclusion in the study	14 (11.0-16.0)
Age of the disease onset	11 (6.0-14.0)
Diagnosis
Ulcerative collitis	25 (25.0)
Crohn’s disease	73 (75.0)
IBD course
Acute (< 6 months since the onset)	10 (10)
Chronic persistent (no remission episodes > 6 months duration during the relevant treatment)	29 (30)
Chronic relapsed (remission > 6 months)	60 (60)
Extra-intestinal features	15 (15.3)
IBD activity at the diagnoses
CD, PCDAI, points	37 (25-45)
UC, PUCAI, points	35 (33-45)
IBD activity at the study inclusion
CD, PCDAI, points	15 (0.0-30.0)
UC, PUCAI, points	2.5 (0.0-10.0)
Biologic treatment before the study	76 (77.5)
Infliximab	48 (70.6)
Adalimumab	21(30.8)
Vedolizumab	7 (10.3)
Number of biologics before the study inclusion
one	59 (86.8)
two	6 (8.8)
three	3 (4.4)
Current treatment with TNF-α inhibitors	41 (61.2)
Increased dose or decreased intervals between TNF-α inhibitors	23 (42.6)
Duration of treatment with TNF-α inhibitors, (months)	3.5 (1.2-22.0)
Systemic corticosteroids (> 1 mg/kg) at onset	56 (60.1)
Duration of systemic corticosteroids, months	2.0 (1.0-3.0)
Conventional DMARDS
Azathyaprine	64 (65.3)
Methotrexate	22 (22.5)
6-mercaptopurine	10 (10.2)
Tacrolimus	2 (2.0)
Topical anti-inflammatory drugs	39 (39.8)
Surgical treatment, related to IBD	12 (12.4)
Conventional DMARDs
At onset	91 (92.8)
At study inclusion	51 (42.3)

IBD: Inflammatory bowel disease; CD: Crohn's disease; UC: Ulcerative colitis; PCDAI: Pediatric Crohn's disease activity index; PUCAI: Pediatric ulcerative colitis activity index; TNF-α: Tumor necrosis factor alpha; DMARDs: Disease-modifying anti-rheumatic drugs.